Rallybio Q2 revenue falls, net loss narrows

Rallybio

07/08/2025 13:09

Overview

Rallybio Q2 revenue dips to $0.2 mln from $0.3 mln in 2024

Net loss narrows to $9.7 mln from $16.2 mln in Q2 2024

Co sells REV102 interest for up to $25 mln, extending cash runway

Outlook

Rallybio expects RLYB116 study data in 3Q and 4Q 2025

Company's cash runway extended into mid-2027 after REV102 sale

Rallybio anticipates complete complement inhibition in RLYB116 study

Company focuses RLYB116 on PTR and APS conditions

Result Drivers

REVENUE DECLINE - Decrease in revenue attributed to changes in collaboration agreements with Johnson & Johnson

R&D EXPENSES DROP - Lower R&D expenses due to decreased development costs for RLYB212 and other programs

CASH INFUSION - Sale of REV102 interest to Recursion Pharmaceuticals extends cash runway into mid-2027

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$9.70 mln
Q2 Basic EPS
-$0.22
Q2 Income From Operations
-$10.06 mln
Q2 Operating Expenses
$10.27 mln


Press Release: ID:nBw38yYrla

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)